视神经脊髓炎诊疗实践及新冠疫情背景下的处方变化：一项针对神经科医生的调查
Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists.
作者信息
Rezaei Shawheen J, Vogel Andre C, Gazdag Brittany, Alakel Nicholas, Kumar Aditya Ravi, Mateen Farrah J
机构信息
Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Boston, USA.
ZoomRx, Boston, USA.
出版信息
J Neuroimmunol. 2020 Sep 15;346:577320. doi: 10.1016/j.jneuroim.2020.577320. Epub 2020 Jul 11.
PURPOSE
This study reports and analyzes the findings from the responses of 192 neurologists in the United States and Canada to a new survey instrument distributed in April 2020 to assess NMO practice and prescribing changes during the Covid19 pandemic.
PRINCIPAL RESULTS
92% of responding neurologists considered their NMO patients to be at an elevated risk of acquiring Covid19. They also indicated sharp declines in visits, delays in treatment and related services, and several unmet needs deterring treatment.
MAJOR CONCLUSIONS
There is a need for evidence-based, comprehensive guidelines for treating NMO patients amid healthcare crises moving forward.
目的
本研究报告并分析了美国和加拿大的192名神经科医生对2020年4月分发的一份新调查问卷的回复结果，该问卷旨在评估新冠疫情期间视神经脊髓炎（NMO）的诊疗情况及处方变化。
主要结果
92%的受访神经科医生认为他们的NMO患者感染新冠病毒的风险较高。他们还指出就诊量急剧下降、治疗及相关服务延迟，以及一些未满足的需求阻碍了治疗。
主要结论
在未来应对医疗危机时，需要有基于证据的、全面的指南来治疗NMO患者。
Zotero 插件